Quiz

Quiz: TD Guidelines and Diagnostic Criteria

05/27/2021

Popular Now

News

Injectable Risperidone Shows Positive Results in Phase 3 Trial

01/14/2021

A phase 3 clinical trial evaluating the efficacy of extended-release injectable risperidone for patients with schizophrenia showed a statistically significant delay in time to relapse, compared to the placebo.

A phase 3 clinical trial...

01/14/2021

Psychiatry & Behavioral Health

News

Reducing TD Symptoms May Boost Overall Mental Health

06/17/2020

Treatment of tardive dyskinesia (TD) with vesicular monoamine transporter 2 (VMAT2) inhibitors may improve patients’ overall psychiatric condition in addition to reducing TD symptoms, a study of real-world data found.

Treatment of tardive dyskinesia...

06/17/2020

Psychiatry & Behavioral Health

News

Increased Use of LAIs Could Improve Schizophrenia Outcomes, Meta-Analysis Finds

04/20/2021

For the maintenance treatment of schizophrenia, long-acting injectable antipsychotics (LAIs) were associated with a lower risk of hospitalization or relapse than oral antipsychotics in a comparative meta-analysis of 137 studies spanning 3...

For the maintenance treatment of...

04/20/2021

Psychiatry & Behavioral Health

News

The Bystander: A First-Person Perspective on Being Blind to Tardive Dyskinesia

06/15/2021

In the “TD360” presentation at the 2018 Psych Congress meeting, Dr. Rakesh Jain passionately challenged the audience to “not walk away” from acknowledging that we all have patients with tardive dyskinesia (TD). This struck close to home for...

In the “TD360” presentation at...

06/15/2021

Psychiatry & Behavioral Health

Education

Continuing Education: Excessive Daytime Sleepiness: Clinical Considerations for Patients with Comorbid Psychiatric Disorders

07/01/2021

Psychiatry & Behavioral Health

Sign Up

Psychiatry & Behavioral Health Newsletter

Quiz: TD Guidelines and Diagnostic Criteria

Popular Now

Sign Up

Specialties

Events

Year Round Education

HMP Global Products